Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation.
Analyst Price Forecast Suggests 277.88% Upside
As of December 23, 2024, the average one-year price target for Unity Biotechnology is $6.80/share. The forecasts range from a low of $6.06 to a high of $8.40. The average price target represents an increase of 277.88% from its latest reported closing price of $1.80 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Unity Biotechnology is 10MM, an increase of ∞%. The projected annual non-GAAP EPS is -4.05.
What is the Fund Sentiment?
There are 52 funds or institutions reporting positions in Unity Biotechnology. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to UBX is 1.18%, an increase of 382.47%. Total shares owned by institutions increased in the last three months by 0.84% to 3,522K shares. 
The put/call ratio of UBX is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Arch Venture holds 1,005K shares representing 5.96% ownership of the company. No change in the last quarter.
Alyeska Investment Group holds 920K shares representing 5.46% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 396K shares representing 2.35% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 195K shares representing 1.16% ownership of the company. No change in the last quarter.
Geode Capital Management holds 163K shares representing 0.97% ownership of the company. In its prior filing, the firm reported owning 149K shares , representing an increase of 8.70%. The firm decreased its portfolio allocation in UBX by 42.36% over the last quarter.
Unity Biotechnology Background Information
(This description is provided by the company.)
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
